Comparative Study on the Efficacy and Safety of Ondansetron Oral Membrane for the Prevention of Vomiting During Moderate Hypoemetic Chemotherapy

Inclusion Criteria: * Patients aged 4 to 15 years who have been diagnosed with malignant tumor through pathological examination and need to receive chemotherapy, gender is not limited; * Receive moderate and low grade emetic chemotherapy; * Patients with a score greater than 60 or higher have a life expectancy greater than 3 months; * The patients were enrolled voluntarily, and the family members signed the informed consent, and the family members had good compliance and accurately recorded the vomiting diary. Exclusion Criteria: * Children allergic to 5HT3 antagonists; * Active infection; * Abnormal bone marrow function (absolute neutrophil count \<1000/mm3 platelet count \<100000/mm3); * Abnormal renal function in serum creatinine beyond the upper age limit of normal (ULN); * Abnormal liver function of serum aspartate aminotransferase and alanine aminotransferase, age and serum bilirubin are 1.5 times that of ULN; * vomiting 24 hours before chemotherapy begins; * Start systemic corticosteroid therapy within 72 hours prior to study drug use, or plan to receive corticosteroids as part of a chemotherapy regimen; * Patients with benzodiazepines or opioids